Dendritic cells pulsed with peptides of gp63 induce differential protection against experimental cutaneous leishmaniasis.
The need for a vaccine against Leishmania spp., a major cause of worldwide morbidity and mortality, is urgent. We tested the efficacy of an experimental vaccination in murine models of cutaneous leishmaniasis, using dendritic cells (DCs) pulsed with synthetic or native parasite antigens. DCs pulsed with peptide 154-169aa of gp63 or soluble promastigote lysate (SPL) triggered antigen-specific immune responses and efficiently reduced lesion formation and parasite load of genetically susceptible BALB/c mice infected with Leishmania major. This effect was accompanied by a modulation of the cellular immune response towards a Th1 profile. Vaccination of genetically resistant CBA mice with DCs pulsed with peptide 154-169aa or SPL did not affect the course of the disease, whereas pulsing with the epitope 467-482aa of gp63 resulted in disease exacerbation, accompanied by a switch to a Th2 profile. In view of our continuously growing knowledge about the immunobiology of DCs, these findings suggest that vaccination with DCs pulsed with defined peptides could be a strategy against infectious diseases. Peptide selection is a prerequisite as they can differentially regulate the type of immune response in susceptible or resistant hosts.
Laboratory of Cellular Immunology, Institute Pasteur Hellenique, Athens, Greece.
P
P
Tsagozis
E
E
Karagouni
E
E
Dotsika
D000818:Animals; D000953:Antigens, Protozoan / Q000276:immunology; D001822:Body Burden; D001854:Bone Marrow Cells / Q000187:drug effects / Q000276:immunology; D016207:Cytokines / Q000096:biosynthesis; D003713:Dendritic Cells / Q000187:drug effects* / Q000276:immunology*; D007111:Immunity, Cellular; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000235:genetics; D016773:Leishmaniasis, Cutaneous / Q000276:immunology / Q000469:parasitology / Q000517:prevention & control*; D008666:Metalloendopeptidases / Q000276:immunology* / Q000627:therapeutic use*; D051379:Mice; D008807:Mice, Inbred BALB C; D008808:Mice, Inbred CBA; D010455:Peptides / Q000627:therapeutic use*; D016052:Protozoan Vaccines / Q000627:therapeutic use*; D018417:Th1 Cells / Q000276:immunology; D014611:Vaccination
D000953:Antigens, Protozoan; D016207:Cytokines; D007074:Immunoglobulin G; D010455:Peptides; D016052:Protozoan Vaccines; D008666:Metalloendopeptidases; C055146:glycoprotein gp63, Leishmania